Hims & Hers (HIMS) Earnings Call Transcript

The Motley Fool

by newsfeedback@fool.com (Motley Fool Transcribing)

February 23, 2026

AI-Generated Deep Dive Summary

Hims & Hers (HIMS) delivered strong financial results in its latest earnings call, highlighting robust revenue growth and expansion across key metrics. The company reported quarterly revenue of $618 million, a 28% year-over-year increase, with annual revenue reaching $2.35 billion, up 59% from the previous year. Subscribers exceeded 2.5 million, marking nearly one million net additions since 2023. Notably, 65% of subscribers are now using personalized treatments, reflecting a significant shift in consumer behavior toward tailored health solutions. The company’s growth was driven by strong performance across both its Hims and Hers brands. In the U.S., Hims achieved over 30% revenue growth, fueled by demand for daily sexual health and combination treatments. The Hers brand also performed exceptionally well, achieving triple-digit revenue growth and accounting for nearly 40% of U.S. revenue. Internationally, Hims & Hers expanded significantly, with revenue surging nearly 400% year-over-year to $134 million in 2025, entering new markets including Germany, the U.K., Ireland, Spain, France, and Canada. Financially, Hims & Hers demonstrated improving profitability, with adjusted EBITDA reaching $66 million for the quarter (an 11% margin) and $318 million for the full year (a 14% margin), up nearly 80% year-over-year. Despite a slight decline in gross margin due to increased international revenue and operational adjustments, the company’s marketing expenses improved by seven percentage points year-over-year, showing progress in optimizing its spend. Looking ahead, Hims & Hers provided guidance for 2026, projecting revenue between $2.7 billion and $2.9 billion, representing a 15%-24% increase. Adjusted EBITDA is expected to range from $300 million to $375 million, with a midpoint margin of 12%. The company also highlighted its confidence in new product categories, including labs, hormone therapies, and menopause, which are projected to reach over $100 million in annual revenue within the near future. Strategic initiatives such as acquisitions (including Zava, LiveWell, and Urbio) and investments in R&D and international expansion were emphasized as key drivers of future growth. The company’s focus on innovation, coupled with its ability to scale efficiently,

Verticals

financeinvesting

Originally published on The Motley Fool on 2/23/2026